Last reviewed · How we verify

INDIUM PENTETREOTIDE

FDA-approved approved Recombinant protein Quality 5/100

INDIUM PENTETREOTIDE is a drug. It is currently FDA-approved (first approved 1994).

At a glance

Generic nameINDIUM PENTETREOTIDE
ModalityRecombinant protein
PhaseFDA-approved
First approval1994

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about INDIUM PENTETREOTIDE

What is INDIUM PENTETREOTIDE?

INDIUM PENTETREOTIDE is a Recombinant protein drug.

When was INDIUM PENTETREOTIDE approved?

INDIUM PENTETREOTIDE was first approved on 1994.

What development phase is INDIUM PENTETREOTIDE in?

INDIUM PENTETREOTIDE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing